Quality of life of healthy subjects and patients with arthritis and diabetes mellitus in Bayelsa State, Niger Delta region

Suleiman, Ismail A.; Henry, Messaih T.; Kpokiri, Eneyi

doi:10.4314/tjpr.v16i7.34

Cited by 4 publications

(4 citation statements)

References 16 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…19 Their results are almost similar to the present study. In 2014, in Nigeria, the direct cost of type 2 diabetes was $28,457 per patient, 20 which is higher than our study. In 2015, on average, the annual cost of treating one case of diabetes mellitus (DM) in Latin America and the Caribbean was estimated between US $1088 and US $1818.…”

Section: Resultscontrasting

confidence: 69%

Economic burden of type 2 diabetes in Iran: A cost‐of‐illness study

Jalilian

Heydari

Imani

et al. 2023

Health Science Reports

View full text Add to dashboard Cite

Background and Aims: Type 2 diabetes mellitus (T2DM) is a prevalent public health problem worldwide, and the economic burden of the disease poses one of the main challenges for health systems in low-and middle-income countries. This study aimed to estimate the economic burden of T2DM in Iran, in 2018.Methods: This was a cost-of-illness study. Three hundred and seventy-five patients with T2DM who were referred to Imam Reza and Sina's educational and therapeutic centers and Asad Abadi clinic in Tabriz, Iran, in 2018 were included. A researcherconstructed checklist was used for data collection. Data were analyzed using EXCEL and SPSS software version 22.Results: Total economic burden of diabetes was estimated at 152,443,862,480.3

show abstract

Section: Resultscontrasting

confidence: 69%

Economic burden of type 2 diabetes in Iran: A cost‐of‐illness study

Jalilian

Heydari

Imani

et al. 2023

Health Science Reports

View full text Add to dashboard Cite

show abstract

“…A gradual increase in publications was observed in the years 2015–2017. (Afroz et al, 2019 ; Akari et al, 2013 ; Andersson et al, 2020 ; Anja & Laura, 2017 ; Anja & Laura, 2017 ; Bommer et al, 2017 ; Bommer et al, 2018 ; Boyanov et al, 2011 ; Bruno et al, 2012 ; Chatterjee et al, 2011 ; Chow et al, 2018 ; Elgart et al, 2014 ; Erzse et al, 2019 ; Hex et al, 2012 ; Hussain et al, 2014 ; Ibrahim, 2014 ; Javanbakht et al, 2011 ; Karachaliou et al, 2014 ; Kattel et al, 2019 ; Khan et al, 2020 ; Köster et al, 2011 ; Köster et al, 2011 ; Lesniowska & Skrzekowska-Baran, 2011 ; Leśniowska et al, 2014 ; Marcellusi et al, 2016 ; Mokdad et al, 2015 ; Palmer et al, 2012 ; Quaye et al, 2011 ; Riewpaiboon et al, 2011 ; Sortsoe et al, 2016 ; Suleiman & Festus, 2015 ; Todorova et al, 2012 ; Ulrich et al, 2016 ; Ying et al, 2011 ; Zhuo et al, 2014 ). Further details can be seen in Figure 2 .…”

Section: Preview Of the Proceduresunclassified

A systematic review of the economic burden of diabetes mellitus: contrasting perspectives from high and low middle-income countries

Butt,

Ong,

Rafiq

et al. 2024

Journal of Pharmaceutical Policy and Practice

View full text Add to dashboard Cite

Introduction Diabetes increases preventative sickness and costs healthcare and productivity. Type 2 diabetes and macrovascular disease consequences cause most diabetes-related costs. Type 2 diabetes greatly costs healthcare institutions, reducing economic productivity and efficiency. This cost of illness (COI) analysis examines the direct and indirect costs of treating and managing type 1 and type 2 diabetes mellitus. Methodology According to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, Cochrane, PubMed, Embase, CINAHL, Scopus, Medline Plus, and CENTRAL were searched for relevant articles on type 1 and type 2 diabetes illness costs. The inquiry returned 873 2011–2023 academic articles. The study included 42 papers after an abstract evaluation of 547 papers. Results Most articles originated in Asia and Europe, primarily on type 2 diabetes. The annual cost per patient ranged from USD87 to USD9,581. Prevalence-based cost estimates ranged from less than USD470 to more than USD3475, whereas annual pharmaceutical prices ranged from USD40 to more than USD450, with insulin exhibiting the greatest disparity. Care for complications was generally costly, although costs varied significantly by country and problem type. Discussion This study revealed substantial heterogeneity in diabetes treatment costs; some could be reduced by improving data collection, analysis, and reporting procedures. Diabetes is an expensive disease to treat in low- and middle-income countries, and attaining Universal Health Coverage should be a priority for the global health community.

show abstract

“…Bayelsa state of Nigeria is not free of the scourge of hypertension. The literature search did report the research efforts of some scholars in the Niger Delta region, such as the work on health related quality of life of hypertensive and diabetic patients by Ganiyu et al 2015 [18] and that of arthritis and diabetes patients by Suleiman et al, 2016 [19], among others. The main goal of the study is to describe the management of hypertension in two Nigerian tertiary health facilities in Bayelsa state of Nigeria with a view to observing similarities and differences observed in all facets and steps of management.…”

Section: Introductionmentioning

confidence: 99%

Evaluating health related quality of life among hypertensive patients: An educational intervention study

Joseph¹,

Eniojukan²,

Suleiman³

et al. 2022

Int. J. Sci. Res. Arch.

View full text Add to dashboard Cite

The health care sector has shown increased interest in humanistic outcomes of therapy. Health related quality of life (HRQOL) evaluation among patients receiving treatment for chronic diseases is now widely applied. Hence, the effect of education on the HRQOL of hypertensive patients was evaluated in two tertiary health facilities; FMC, Yenagoa and NDUTH, Okolobiri in Bayelsa State, Nigeria. Trained Pharmacist interviewed willing hypertensive patients between 21-80 years of age at the cardiology clinics of the health facilities using the MINICHAL questionnaire which is specific for hypertension. A convenient sampling technique was adopted. Demographic characteristics were also obtained. The responses (425) were analyzed and observed. To evaluate the effect of drugs and educational intervention, an interactive health talks on hypertension was held at their cardiology clinic weekly for six weeks. Two months later the questionnaire was re-administered. The responses post intervention (297) was analyzed. The results were then compared. The MINICHAL rates HRQOL as best=0 to worst=51. HRQOL score of 12.96 to 8.00 in FMC Yenagoa and 8.70 to 8.55 in NDUTH Okolobiri, pre and post intervention respectively was observed. Though not significant (P=0.3998), the study revealed that educational intervention brought about a positive trend in demographic characteristics. Age, marriage and education were indicated as strong indicators of HRQOL. Educational intervention on hypertension improves patient’s HRQOL. Patients’ education and counseling should be a continuous tool in patient management.

show abstract

Quality of life of healthy subjects and patients with arthritis and diabetes mellitus in Bayelsa State, Niger Delta region

Cited by 4 publications

References 16 publications

Economic burden of type 2 diabetes in Iran: A cost‐of‐illness study

Economic burden of type 2 diabetes in Iran: A cost‐of‐illness study

A systematic review of the economic burden of diabetes mellitus: contrasting perspectives from high and low middle-income countries

Evaluating health related quality of life among hypertensive patients: An educational intervention study

Contact Info

Product

Resources

About